Honasa Consumer Limited has acquired a 58% majority stake in Fluence Pharma through a newly incorporated subsidiary, Honasa Health Private Limited. This marks Honasa Consumer's entry into the nutraceuticals category.
Fluence Pharma reported revenue of approximately Rs 40 crore and an EBITDA margin of over 20% in FY26. Fluence Pharma has over a decade of in-clinic performance and is trusted by more than 3,000 practicing dermatologists. The Indian nutraceuticals market is valued at over Rs 16,000 crore.
Honasa Consumer will scale a B2C nutrition portfolio by combining Fluence's patented Cyclical Nutrition Therapy with its own brand building, consumer insights, and digital-first distribution. Cyclical Nutrition Therapy involves OTC supplements administered in a structured sequence to maximise efficacy.
Varun Alagh, Co-founder and CEO of Honasa Consumer Limited, said the next decade in beauty will be defined by the convergence of science-backed skin and hair care with nutraceuticals. Fluence Pharma was founded by CEO Amit Bhusari and Dr. Rajendra Singh Rajput, a trichologist and dermatologist who invented Cyclical Nutrition Therapy. Bhusari has over 20 years of category expertise in nutraceuticals. Fluence Pharma offers condition and gender-specific OTC supplement doses for complex hair and skin conditions, backed by US and India patents.
Dheeraj Nagpal has been appointed CEO of Honasa Health, bringing over 15 years of consumer business experience including co-founding the nutraceuticals brand Zingavita. Nagpal previously held leadership roles at Zomato and American Express. Honasa Consumer services over 95% of pin codes across India through its omni-channel network and has a presence in close to 300,000 FMCG retail outlets.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.